CRISPR Therapeutics AG

NasdaqGM:CRSP Voorraadrapport

Marktkapitalisatie: US$4.4b

CRISPR Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

CRISPR Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 34.9% en 54.1% per jaar. De winst per aandeel zal naar verwachting groeien met 35.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -7.9% zijn.

Belangrijke informatie

34.9%

Groei van de winst

35.2%

Groei van de winst per aandeel

Biotechs winstgroei27.5%
Inkomstengroei54.1%
Toekomstig rendement op eigen vermogen-7.9%
Dekking van analisten

Good

Laatst bijgewerkt08 Nov 2024

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Recent updates

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Crispr Therapeutics: Poised For A Major Turnaround

Oct 28

CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Oct 02
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Sep 13

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Sep 04
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 14

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Aug 09
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 07

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Jul 13

Crispr Therapeutics: Beaten Down But Not Broken

Jul 07

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Jun 18
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 10

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Jun 03

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

May 13
Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

May 10
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

May 09

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

May 03

Crispr Therapeutics: Now Is The Time To Buy

Apr 24

Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Apr 16
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 26

There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Feb 22
There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Crispr Therapeutics: Cautiously Optimistic

Feb 22

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Feb 01

Crispr Therapeutics: Commercial Validation Is The Next Step

Jan 18

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Jan 11

CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

Dec 25
CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Nov 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Oct 05
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

Sep 14
CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Jul 24
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Jun 28
Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Apr 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 06
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

Dec 08
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag

Sep 28

Crispr: Elucidating And Forecasting Key Developments

Sep 21

Crispr Therapeutics: Nearing Harvest Season

Sep 08

Winst- en omzetgroeiprognoses

NasdaqGM:CRSP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026559-262-294N/A16
12/31/2025133-438-370N/A27
12/31/202418-430-182N/A24
9/30/2024203-240N/AN/AN/A
6/30/2024202-266-129-122N/A
3/31/2024272-217-169-159N/A
12/31/2023371-154-272-260N/A
9/30/2023170-354-295-278N/A
6/30/2023170-416-362-343N/A
3/31/2023100-524-377-352N/A
12/31/20221-650-533-496N/A
9/30/202214-681-509-468N/A
6/30/202215-633-516-445N/A
3/31/2022915312414504N/A
12/31/2021915378457539N/A
9/30/2021902412465544N/A
6/30/2021902447502549N/A
3/31/20211-392-309-287N/A
12/31/20201-349-257-238N/A
9/30/202077-211-167-154N/A
6/30/2020289204555N/A
3/31/2020289464048N/A
12/31/2019290675057N/A
9/30/2019213-111825N/A
6/30/20191-200-133-128N/A
3/31/20192-185-121-117N/A
12/31/20183-165-99-96N/A
9/30/201835-117-85-83N/A
6/30/201837-91N/A-79N/A
3/31/201840-75N/A-69N/A
12/31/201741-68N/A-70N/A
9/30/201711-51N/A-75N/A
6/30/201710-41N/A-71N/A
3/31/20177-36N/A-69N/A
12/31/20165-23N/A-53N/A
9/30/20163-53N/A33N/A
6/30/20162-44N/A40N/A
3/31/20161-31N/A51N/A
12/31/20150-26N/A59N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CRSP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CRSP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CRSP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CRSP ( 54.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CRSP ( 54.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat CRSP binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven